Goldblum JR, Weiss SW, Folpe AL. Enzinger and Weiss’s soft tissue tumors E-Book. Elsevier Health Sciences; 2013.

Google Scholar 

Arifi S, Belbaraka R, Rahhali R, Ismaili N. Treatment of Adult Soft Tissue Sarcomas: An Overview. Rare Cancers Ther. 2015;3(1):69–87.

Article  PubMed  PubMed Central  Google Scholar 

Bleloch JS, Ballim RD, Kimani S, Parkes J, Panieri E, Willmer T, et al. Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol. 2017;9(10):637–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansen T, Katenkamp K, Brodhun M, Katenkamp D. Low-grade fibrosarcoma–report on 39 not otherwise specified cases and comparison with defined low-grade fibrosarcoma types. Histopathology. 2006;49(2):152–60.

Article  CAS  PubMed  Google Scholar 

Tan MC, Brennan MF, Kuk D, Agaram NP, Antonescu CR, Qin LX, et al. Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma. Ann Surg. 2016;263(3):593–600.

Article  PubMed  PubMed Central  Google Scholar 

von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(7):815–33.

Article  Google Scholar 

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397–410.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, et al. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020;323(13):1266–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14(3):869–77.

Article  CAS  PubMed  Google Scholar 

Italiano A, Mathoulin-Pelissier S, Cesne AL, Terrier P, Bonvalot S, Collin F, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117(5):1049–54.

Article  PubMed  Google Scholar 

Meyer M, Seetharam M. First-Line Therapy for Metastatic Soft Tissue Sarcoma. Curr Treat Options Oncol. 2019;20(1):6.

Article  PubMed  Google Scholar 

Carbonnaux M, Brahmi M, Schiffler C, Meeus P, Sunyach MP, Bouhamama A, et al. Very long-term survivors among patients with metastatic soft tissue sarcoma. Cancer Med. 2019;8(4):1368–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coley WB. II. Contribution to the Knowledge of Sarcoma. Ann Surg. 1891;14(3):199–220.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017;5(1):100.

Article  PubMed  PubMed Central  Google Scholar 

Burgess MA, Bolejack V, Schuetze S, Tine BAV, Attia S, Riedel RF, et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. J Clin Oncol. 2019;37(15suppl):11015.

Article  Google Scholar 

Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556–60.

Article  CAS  PubMed  Google Scholar 

Italiano A, Bellera C, D’Angelo S. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. J Hematol Oncol. 2020;13(1):55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wood GE, Meyer C, Petitprez F, D’Angelo SP. Immunotherapy in Sarcoma: Current Data and Promising Strategies. Am Soc Clin Oncol Educ Book. 2024;44(3):e432234.

Article  PubMed  Google Scholar 

Cao Y, Wang W, Xu H, Yi H, Gao Y, Wan M, et al. Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials. Int Immunopharmacol. 2025;148:114070.

Article  CAS  PubMed  Google Scholar 

Kallen ME, Hornick JL. The 2020 WHO Classification: What’s New in Soft Tissue Tumor Pathology? Am J Surg Pathol. 2021;45(1):e1–23.

Article  PubMed  Google Scholar 

Deng J, Zeng W, Kong W, Shi Y, Mou X. The study of sarcoma microenvironment heterogeneity associated with prognosis based on an immunogenomic landscape analysis. Front Bioeng Biotechnol. 2020;8:1003.

Article  PubMed  PubMed Central  Google Scholar 

Subramanian A, Nemat-Gorgani N, Ellis-Caleo TJ, van Sears IDGP, Somani TJ. Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy. Nat Cancer. 2024;5(4):642–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and Metabolism in the Tumor Microenvironment. Cell Metab. 2019;30(1):36–50.

Article  CAS  PubMed  Google Scholar 

Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023;186(8):1627–51.

Article  CAS  PubMed  Google Scholar 

Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(6):402–21.

Article  PubMed  Google Scholar 

Kather JN, Hörner C, Weis CA, Aung T, Vokuhl C, Weiss C, et al. CD163 + immune cell infiltrates and presence of CD54 + microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. Sci Rep. 2019;9(1):9211.

Article  PubMed  PubMed Central  Google Scholar 

Smolle MA, Herbsthofer L, Goda M, Granegger B, Brcic I, Bergovec M, et al. Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma. Oncoimmunology. 2021;10(1):1896658.

Article  PubMed  PubMed Central  Google Scholar 

Hu C, Chen B, Huang Z, Liu C, Ye L, Wang C, et al. Comprehensive profiling of immune-related genes in soft tissue sarcoma patients. J Transl Med. 2020;18(1):337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–26.

Article  PubMed  PubMed Central  Google Scholar 

Klaver Y, Rijnders M, Oostvogels A, Wijers R, Smid M, Grünhagen D, et al. Differential quantities of immune checkpoint-expressing CD8 t cells in soft tissue sarcoma subtypes. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2019-000271.